Heterocyclic amines, cytochrome P4501A2, and N-acetyltransferase: Issues involved in incorporating putative genetic susceptibility markers into epidemiological studies

Annals of Epidemiology

Volumn 7, Issue 5, 1997, Pages 350-356

  Sinha, Rashmi ^a   Caporaso, Neil ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytochrome P4501A2; Genotype; Heterocyclic Amines; Inducible Enzymes; N acetyltransferase MelQx; Phenotype

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450; HETEROCYCLIC AMINE;

ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; EPIDEMIOLOGICAL DATA; FEMALE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 0030805080     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(97)00027-6     Document Type: Article

References (30)

1. Degawa M, Tanimura S, Agatsuma T, Hashimoto Y. Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448 isozymes, mainly cytochrome P-448H (P-4501A2), responsible for mutagenic activation of the carcinogenesis in rat liver. Carcinogenesis. 1989;10:1119-1122.
2. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991;12:1839-1845.
3. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teital CH, Massengill JP, Lawson MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-127.
4. D'Errico A, Taioli E, Chenx X, Vineis P. Genetic polymorphisms and the risk of cancer. A review of the literature. Biomarkers. 1996;1:149-173.
5. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauser-Jensen M, and Kadlubar FF. Rapid metabolic phenotypes for acetyl-transferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev. 1994;3:675-682.
6. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129-160.
7. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence. Pharmacogenetics. 1991;1:4-19.
8. Guengerich FP. Cytochrome P450 enzymes. American Scientist. 1993;81:440-447.
9. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci. 1992; 50:1471-1478.
10. Gonzalez FJ. Human cytochromes P450: Problems and prospects. Trends Pharmacol Sci. 1992;13:346-351.
11. Sinha R, Rothman N, Brown E, Mark S, Hoover R, Caporaso N, Levander O, Knize M, Lang N, Kadlubar F. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res. 1994;54:6154-6159.
12. Nerurkar PV, Anderson LM, Snyderwine EG, Park SS, Thorgeirsson SS, Rice JM. Specific induction of hepatic cytochrome P4501a-2 in C57BL/6 and DBA/2 mice treated with 2-amino-3-methylimidazo[4, 5-f]quinolin (IQ). J Biochem Toxicol. 1993;8:175-186.
13. Nakajima MT, Yokoi M, Mizutami SS, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994;3: 413-421.
14. Vatsis KP, Weber WW, Bell DA, Dupret J, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995;5:1-17.
15. Weber WW, Hein DW. N-acetylation pharmacogenetics. Physiol Rev. 1985;37:25-79.
16. Lynch AM, Knize MG, Boobis AR, Gooderham NJ, Davies DS, Murray S. Intra-and interindividual variability in systemic exposure in humans to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, carcinogens present in cooked beef. Cancer Nurs. 1992;52:6216-6223.
17. Boobis AR, Lynch AM, Murray S, et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res. 1994;54:89-94.
18. Sinha R, Rothman N, Brown ED, et al. High concentrations of carcinogen PhIP occurs in chicken but are dependent on the cooking method. Cancer Res. 1995;55:4516-4519.
19. Conney AH, Pantuck EJ, Hsiao KC, Garland WA, Anderson KE, Alvares AP, Kappas A. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther. 1976;20: 633-642.
20. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Res. 1982;42:4875-4917.
21. Horn EP, Tucker MA, Lambert G, Silverman D, Zametkin D, Sinha R, Hartge T, Landi MT, Caporaso NE. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:529-533.
22. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by choroxazone pharmacokinetics. Biochem Pharmacol. 1994;47:1503-1508.
23. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyl-transferase activity: Should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol Biomarkers Prev. 1996;5:449-455.
24. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine [see comments]. Proc Natl Acad Sci USA. 1993; 15;90:11825-11829.
25. Kadlubar FF, Young JF, Lang NP, Caporaso NE, Sinha R, Landi MT. Correspondence re: Letter to the editor by B.K. Tang and W. Kalow on CYP1A2 phenotyping using caffeine. Cancer Epidemiology Biomarkers & Prevention. 1996;5:231-232.
26. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4:109-116.
27. Jackson PR, Tucker GT, Woods HF. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism - hypothesis testing. Br J Clin Pharmacol. 1989;28:655-662.
28. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of genetics polymorphism of debrisoquin hydroxylase in a white British population. J Med Genet. 1980;17:102-105.
29. Jackson PR, Tucker GT, Woods HF. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism - histograms and probit plots. Br J Clin Pharmacol. 1989;28: 647-663.
30. Deleo JM. Receiver operating characteristics laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. Los Alamitos, CA: IEEE Computer Society, 1993.